Diabetes Drugs: Bittersweet Truth of Patent Expiries
With the oral diabetes drugs market at Rs 13,000 crore and growing, a key diabetes medicine Sitagliptin going off patent means a sweet spot for all. How does the billion-dollar pharma industry see an opportunity in a market with the highest number of diabetes patients in the world. Host Kiran Somvanshi chats with…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like The Morning Brief →
#041 Prices of Expensive Diabetes Drugs Are Falling And More Manufacturers Are Rushing In
Can India become the pharmacy for weight-loss drugs?
The price drop in weight-loss drugs Indian pharma can’t handle
India’s Diabetes Crisis: A Ticking Time Bomb
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.